Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Matrixx Prompts Supreme Court To Consider What Firms Must Disclose

This article was originally published in The Tan Sheet

Executive Summary

A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies

You may also be interested in...



Search For Balance Drives Supreme Court Debate In Matrixx Case

In litigation between Matrixx Initiatives and shareholders, the Supreme Court appears concerned with striking a balance between requiring the disclosure of any facts that could affect investors' decisions and the release of so much information that important facts are obscured.

Search For Balance Drives Supreme Court Debate In Matrixx Case

In litigation between Matrixx Initiatives and shareholders, the Supreme Court appears concerned with striking a balance between requiring the disclosure of any facts that could affect investors' decisions and the release of so much information that important facts are obscured.

Search For Balance Drives Supreme Court Debate In Matrixx Case

In litigation between Matrixx Initiatives and shareholders, the Supreme Court appears concerned with striking a balance between requiring the disclosure of any facts that could affect investors' decisions and the release of so much information that important facts are obscured.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel